All News
ICYMI: EGPA Review
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Read Article
ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management
The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.
Read Article
ICYMI: B Cells at the Brink in Sjögren Disease
A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.
Read Article
B cell Targeting in SLE
MedPage Today
Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.
Read Article
Late-Breaking Studies at EULAR 2026
MedPage Today
Late-breaking abstracts presented at the European Alliance of Associations for Rheumatology's (EULAR) annual meeting, held here last week, addressed a wide range of clinical conc
Read Article
Insights into Treating Lupus - A Rheum Survey
RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed https://t.co/HNaUK5Q9uq
Dr. John Cush RheumNow ( View Tweet)
RT @rheumarampa
"There’s more work to do” as Dr. Floris van Gaalen summarizes the challenges in peripheral SpA
-pSpA has limited lab value testing like imaging, clinical diagnosis
- few clinical trials to support tx guidelines
- SPARTACUS trial: GOL vs. MTX in early pSpA
Dr. John Cush RheumNow ( View Tweet)
RT @yuz6yusof
#EULAR2026 OP0337 In double blind LTE WILLOW study, cutaneous efficacy (change in CLASI, CLASI 70/50) was maintained in Enpatoran, TLR 7/8-i by WK48. Those switched from PBO to ENP at WK24 also showed equal efficacy to ENP-ENP group. Promising treatment for #CLE
Dr. John Cush RheumNow ( View Tweet)
RT @aurelierheumo
A long release version of xanthine oxidase inhibitor in gout
-442 pts 36 wks
-HR091506 vs febuxostat
-SUA <300 μmol/L: 63.8% vs 40.7% (Δ +22.9%, p<0.0001)
-higher SUA reduction vs baseline
-Similar overall TEAEs (~90%)
A molecule to keep an eye on!
#LB0008
Dr. John Cush RheumNow ( View Tweet)
ICYMI: B Cells at the Brink in Sjögren Disease
The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder. https://t.co/OBFqHYof5m
Dr. John Cush RheumNow ( View Tweet)
RT @minidey #OP0342 Interim real-world ASTER data showed anifrolumab improved overall SLEDAI-2K scores & reduced disease activity across multiple organ systems over 12 months, particularly mucocutaneous & MSK domains. Nearly 30% achieved SLEDAI-2K=0 at 1 year. #EULAR2026
Dr. John Cush RheumNow ( View Tweet)
Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/31IRNXckym
Dr. John Cush RheumNow ( View Tweet)
B cell Targeting in SLE
Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.
https://t.co/wGaZPnXfID https://t.co/a0fNvdcrbQ
Dr. John Cush RheumNow ( View Tweet)
RHEUM SURVEY> Do you prefer a lupus drug if it has a lupus nephritis indication (when your treating non-renal SLE)? Answer here >> https://t.co/1KridYM9n8 https://t.co/zIqNB5Mc0O
Dr. John Cush RheumNow ( View Tweet)
Systematic review of live virus MMR in #JIA had 9 studies (743 pts) showing no flares, good safety & immunogenicity in short term, BUT incomplete or less durable protection in biologic-treated patients, especially for measles & rubella. 5-yrs post MMR, seroprotection was lower if https://t.co/JQhL9o1O4e
Dr. John Cush RheumNow ( View Tweet)
Is there a path to precision medicine in #RA? Theres a substantial unmet need. Immunoengineering is possible thru nanotechnological delivery vectors, cellular therapeutics, & biomaterial scaffolds, with compelling preclinical and early clinical support. https://t.co/gL56EOlt7p https://t.co/IFSHOM8g7w
Dr. John Cush RheumNow ( View Tweet)
From BiTE to TriTE: Progress of T-cell Engagers in RMDs
At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/jjXrf9tcaA
Dr. John Cush RheumNow ( View Tweet)
From BiTE to TriTE: Progress of T-cell Engagers in RMDs
At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/o8Tn77aYRg
Dr. John Cush RheumNow ( View Tweet)
How many CAR-T’s do we need to test drive?
There were 93 abstracts with CAR-T in title at #EULAR2026! Additionally, there was an excellent review (WIN) by Dr. Hector Chinoy. We know lots but have more questions.
https://t.co/FvnqmKSMT4 https://t.co/Qosum9s1UX
Dr. John Cush RheumNow ( View Tweet)
NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK
Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.
https://t.co/8eZyDxL7wu https://t.co/Nvbj1NQb5A
Dr. John Cush RheumNow ( View Tweet)
